| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
Protein tyrosine phosphatases (PTPs). EGF Receptor Substrate 2 (Phospho-Tyr5) is a tyrosine phosphate substrate that is dephosphorylated by PTPs. It is not an inhibitor but a substrate used to measure PTP enzymatic activity. The peptide mimics the phosphorylated autophosphorylation site of EGFR at Tyr992.
|
|---|---|
| ln Vitro |
EGF Receptor Substrate 2 (Phospho-Tyr5) is a substrate for protein tyrosine phosphatases (PTPs). It does not have inhibitory activity; rather, it is cleaved by PTPs, which remove the phosphate group from the phosphorylated tyrosine. The dephosphorylation reaction can be monitored to quantify PTP activity. The peptide corresponds to residues surrounding Tyr992 of EGFR, a key autophosphorylation site.
|
| ln Vivo |
EGF Receptor Substrate 2 (Phospho-Tyr5) is not used as a therapeutic agent. It is a research tool for ex vivo measurement of PTP activity in tissue lysates or biological samples. Researchers can measure PTP activity in samples from animal models of disease (e.g., cancer, diabetes) to assess the role of specific PTPs in disease progression.
|
| Enzyme Assay |
For non-cellular assays, purified protein tyrosine phosphatase (PTP) is incubated with EGF Receptor Substrate 2 (Phospho-Tyr5) in assay buffer (e.g., 50 mM Tris-HCl, pH 7.5, 1 mM DTT, 1 mM EDTA). The reaction is carried out at 30degC for 10-30 minutes. Inorganic phosphate release is measured using a malachite green-based colorimetric assay (absorbance at 620 nm) or using a coupled enzyme assay. Alternatively, the dephosphorylated peptide can be quantified by HPLC or mass spectrometry.
|
| Cell Assay |
EGF Receptor Substrate 2 (Phospho-Tyr5) is typically not used in live cell assays because it is a peptide that may not be cell-permeable. Instead, cell lysates are prepared from treated cells, and PTP activity is measured by incubating the lysate with the peptide substrate. The reaction is carried out in 96-well plates at 30degC for 30-60 minutes, and phosphate release is measured using the malachite green method. Results are normalized to protein concentration.
|
| Animal Protocol |
For ex vivo activity measurement, animals are treated with test compounds that may modulate PTP activity. Tissues (e.g., liver, muscle, tumor) are harvested and homogenized in lysis buffer. Lysates are clarified by centrifugation and protein concentration is quantified. Lysates are then incubated with EGF Receptor Substrate 2 (Phospho-Tyr5) (10-100 uM) for 30-60 minutes at 30degC. Phosphate release is measured to determine PTP activity, and results are normalized to protein concentration.
|
| ADME/Pharmacokinetics |
EGF Receptor Substrate 2 (Phospho-Tyr5) is a synthetic peptide that is stable in lyophilized form at -20degC for long-term storage. For use, it is reconstituted in DMSO or aqueous buffer. It has no intrinsic pharmacokinetics as it is used only in vitro or ex vivo. Its stability in assay buffers (pH 7-8) is sufficient for standard PTP activity measurements (2-4 hours). Toxicity of EGF Receptor Substrate 2 (Phospho-Tyr5) is not relevant as it is not used in vivo therapeutically. Standard laboratory safety precautions for handling synthetic peptides should be followed. It is intended for research use only and is non-toxic at the concentrations used in enzymatic assays.
|
| References | |
| Additional Infomation |
EGF Receptor Substrate 2 (Phospho-Tyr5) (CAS: 149261-42-7) has the peptide sequence H-Asp-Ala-Asp-Glu-{pTyr}-Leu-Ile-Pro-Gln-Gln-Gly-OH (where {pTyr} is phosphotyrosine). The molecular formula is C54H82N13O24P and the molecular weight is 1328.28. It is a valuable tool for measuring PTP activity and studying signal transduction pathways involving EGFR. It is not a drug and has no clinical approval.
|
| Molecular Formula |
C54H82N13O24P
|
|---|---|
| Molecular Weight |
1328.28
|
| Exact Mass |
1327.533
|
| CAS # |
149261-42-7
|
| Related CAS # |
EGF Receptor Substrate 2 (Phospho-Tyr5) (TFA);EGF Receptor Substrate 2 (Phospho-Tyr5) (acetate)
|
| PubChem CID |
101685883
|
| Appearance |
White to off-white solid powder
|
| Density |
1.421±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(Predicted)
|
| LogP |
-7.6
|
| Hydrogen Bond Donor Count |
18
|
| Hydrogen Bond Acceptor Count |
25
|
| Rotatable Bond Count |
41
|
| Heavy Atom Count |
92
|
| Complexity |
2740
|
| Defined Atom Stereocenter Count |
11
|
| SMILES |
CC[C@H](C)[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)NCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC2=CC=C(C=C2)OP(=O)(O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)N
|
| InChi Key |
XDGUOGPVOAMJIB-VZAHYZMKSA-N
|
| InChi Code |
InChI=1S/C54H82N13O24P/c1-6-26(4)44(54(87)67-19-7-8-37(67)53(86)62-32(14-17-39(57)69)48(81)60-31(13-16-38(56)68)47(80)58-24-43(76)77)66-52(85)34(20-25(2)3)64-50(83)35(21-28-9-11-29(12-10-28)91-92(88,89)90)65-49(82)33(15-18-40(70)71)61-51(84)36(23-42(74)75)63-45(78)27(5)59-46(79)30(55)22-41(72)73/h9-12,25-27,30-37,44H,6-8,13-24,55H2,1-5H3,(H2,56,68)(H2,57,69)(H,58,80)(H,59,79)(H,60,81)(H,61,84)(H,62,86)(H,63,78)(H,64,83)(H,65,82)(H,66,85)(H,70,71)(H,72,73)(H,74,75)(H,76,77)(H2,88,89,90)/t26-,27-,30-,31-,32-,33-,34-,35-,36-,37-,44-/m0/s1
|
| Chemical Name |
(4S)-5-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[(2S)-2-[[(2S)-5-amino-1-[[(2S)-5-amino-1-(carboxymethylamino)-1,5-dioxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-3-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-(4-phosphonooxyphenyl)propan-2-yl]amino]-4-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-carboxypropanoyl]amino]propanoyl]amino]-3-carboxypropanoyl]amino]-5-oxopentanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O: 50 mg/mL (37.64 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.7529 mL | 3.7643 mL | 7.5285 mL | |
| 5 mM | 0.1506 mL | 0.7529 mL | 1.5057 mL | |
| 10 mM | 0.0753 mL | 0.3764 mL | 0.7529 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
